Univariate analysis using logistic regression showed that EpCAM overexpression was not significantly associated with the clinicopathological characteristics of PCa (Table 3), including age (P = 0.065), pT stage (T3–4 vs. T1–2: P = 0.78), lymph node metastasis (positive vs. negative: P = 0.889), number of lymph node (> 10 vs. ≤ 10: P = 0.39), prostate-specific antigen (PSA) value (  ≥ 10 vs. < 10: P = 0.288), Gleason score (≥  7 vs. ≤  6: P = 0.561), and biochemical recurrence (yes vs. no: P = 0.408). The gene discussed is EPCAM; the disease is posterior cortical atrophy.